Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer

Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer

Abstract Background Immunotherapeutic regulation of the tumor microenvironment in prostate cancer patients is not understood. Most antibody immunotherapies have not succeeded in prostate cancer. We showed previously that high-risk PCa patients have a higher density of tumor infiltrating B-cells in p...

Full description

Bibliographic Details
Main Authors: Stephen T. Ryan, Jing Zhang, Danielle N. Burner, Michael Liss, Emily Pittman, Michelle Muldong, Ahmed Shabaik, Jason Woo, Nicole Basler, Jonathan Cunha, Shabnam Shalapour, Monica V. Estrada, Michael Karin, Karen Messer, Stephen Howell, Christopher J. Kane, Christina A. M. Jamieson
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Journal of Translational Medicine
Subjects:
Prostate cancer
Rituximab
Immunotherapy
CD20
CD3
PD-L1
Online Access:http://link.springer.com/article/10.1186/s12967-020-02370-4

Internet

http://link.springer.com/article/10.1186/s12967-020-02370-4

Similar Items